Donnie Dunagan, MD
Allergy · Augusta, GANPI 1760438444
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 789 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,080, 2.5 times the $1,614 reported in 2019.
Across 789 payments — averaging $23.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$3K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Optinose US, Inc.$927
- CSL Behring$873
- plus $6K from 32 others
What the payments were for
- Food & beverage$18,27298%
- Education$3512%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 180 | $4,106 |
| AstraZeneca | 103 | $2,892 |
| Sanofi | 73 | $2,053 |
| Regeneron Healthcare Solutions, Inc. | 60 | $1,662 |
| Optinose US, Inc. | 45 | $927 |
| CSL Behring | 40 | $873 |
| Pfizer | 45 | $726 |
| Biocryst US Sales Co., LLC | 31 | $661 |
| Novartis | 25 | $586 |
| LEO Pharma Inc. | 16 | $423 |
| Grifols USA, LLC | 22 | $399 |
| Pharming Healthcare, Inc. | 15 | $347 |
| Sanofi-aventis U.S. LLC | 4 | $319 |
| Kaleo, Inc. | 19 | $305 |
| Galderma Laboratories, L.p. | 13 | $298 |
| Genentech USA, Inc. | 14 | $267 |
| Phathom Pharmaceuticals, Inc. | 4 | $253 |
| Teva Pharmaceuticals USA, Inc. | 19 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $176 |
| Octapharma USA, Inc. | 3 | $146 |
| Incyte Corporation | 6 | $128 |
| AbbVie | 5 | $116 |
| Hikma Pharmaceuticals USA | 7 | $114 |
| Boehringer Ingelheim | 6 | $105 |
| Lilly USA, LLC | 3 | $79 |
| Ionis Pharmaceuticals, Inc. | 3 | $75 |
| Cycle Pharmaceuticals Inc | 3 | $71 |
| Amgen | 4 | $66 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $58 |
| Dermavant Sciences, Inc. | 2 | $42 |
| Organon | 2 | $31 |
| ADMA Biomanufacturing LLC | 1 | $27 |
| USWM, LLC | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $18 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few allergy providers in Georgiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 79 | $327,143 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $183,536 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 117 | $94,066 |
| Dupixent PenDupilumab | 12 | $89,816 |
| XolairOmalizumab | 14 | $48,474 |
| AdbryTralokinumab-Ldrm | 13 | $45,074 |
| Breo ElliptaFluticasone/Vilanterol | 67 | $32,678 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $29,535 |
| SymbicortBudesonide/Formoterol Fumarate | 54 | $21,490 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 85 | $19,058 |
| Epinephrine | 66 | $14,325 |
| Azelastine Hcl | 300 | $10,638 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $9,429 |
| Ipratropium Bromide | 220 | $7,784 |
| Arnuity ElliptaFluticasone Furoate | 22 | $6,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringHizentra | $873 | $183,53613 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $4,106 | $133,031206 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,892 | $51,02590 claims |
| LEO Pharma Inc.Adbry | $423 | $45,07413 claims |
| Hikma Pharmaceuticals USAEpinephrine | $114 | $14,32566 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $181 | $5,96013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Georgiaon file to place this against a meaningful peer group, so we don't.
Other allergy in Augusta
- Tesneem ChaudharyAugusta$6K
- Jaya TherattilAugusta$4K
- Thomas ChackoAlpharetta$63K
- Amy HirshAtlanta$14K
- Tricia LeeDecatur$13K
- Theodore LeeAtlanta$11K
- Anu MongiaCartersville$8K
- John HalwigAustell$5K
- Carol WigginsAtlanta$5K
- Ariana BuchananCarrollton$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.